Evidence map›Paper›PMID 36411357›Full record

ArticleAnnals of nuclear medicine2023

Dosimetry and efficacy of a tau PET tracer [

Akihito Ohnishi, Go Akamatsu, Yasuhiko Ikari, Hiroyuki Nishida, Keiji Shimizu, Keiichi Matsumoto, Kazuki Aita, Masahiro Sasaki, Yasuji Yamamoto, Tomohiko Yamane and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of nuclear medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Off-target binding ofAnnals of nuclear medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Akihito Ohnishi *Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Go Akamatsu *Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Yasuhiko IkariDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Hiroyuki NishidaDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Keiji ShimizuDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Keiichi MatsumotoDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Kazuki AitaDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Masahiro SasakiDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Yasuji YamamotoDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Tomohiko YamaneDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Michio SendaDepartment of Molecular Imaging Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan. michio_senda@kcho.jp.ORCID http://orcid.org/0000-0002-7520-0942
Kobe City Medical Center General Hospital · JPJapanese Red Cross Kobe Hospital · JPKyoto College of Medical Science · JPNational Institutes for Quantum Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveA new tau PET tracer [

methodsThree healthy elderly subjects and three AD patients were enrolled. Dynamic whole-body PET scans were acquired for up to 232 min after starting injection of [

resultsNo adverse events were observed. The highest radiation doses were received by the gallbladder (257.7 ± 74.9 μGy/MBq) and the urinary bladder (127.3 ± 11.7 μGy/MBq). The effective dose was 26.8 ± 1.4 μSv/MBq. The parent form ([

conclusionThe findings supported safety and efficacy of [

trial registrationJapan Pharmaceutical Information Center ID, JapicCTI-194972.

Indexed as

Alzheimer DiseaseAgedHumansIsoquinolinesPositron-Emission TomographyRadiometryTissue DistributionIsoquinolinesMK-6240[18F]MK-6240Alzheimer’s diseaseDosimetryJapaneseTau PET

Identifiers

PMID36411357
PMCPMC9902412
OpenAlexW4309669575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.